Lifestyle

OSTEONIC Co., Ltd. Reports Cumulative Third-Quarter Revenue of 39.8 Billion… 'Exports Surpass Domestic Sales'

Company Reports Cumulative Operating Profit of 7.4 Billion Won and Net Profit of 4.8 Billion Won Trauma-Related Exports Rise 114.9%… Efforts Underway to Integrate Spinal Implants and Surgical Robots

KIM JI-WAN
2026-11-16 13:11:02
[Edaily Reporter KIM JI-WAN ] OSTEONIC Co., Ltd.(226400)reported cumulative sales of 39.8 billion won for the first three quarters of this year, driven by expanded overseas sales. Overseas sales slightly exceeded domestic sales in the third quarter as exports of the “Trauma” product line—implants for treating traumatic injuries—more than doubled.

OSTEONIC Co., Ltd. announced on the 16th that it achieved consolidated revenue of 39.8 billion won, operating profit of 7.4 billion won, and net income of 4.8 billion won from January through September of this year.

Export growth was particularly notable in the third-quarter results. During the same period last year, domestic sales totaled 6.16 billion won and exports totaled 5.79 billion won, with domestic sales accounting for a larger share. This year, while both domestic sales and exports increased to approximately 6.8 billion won each, exports edged out domestic sales slightly.

OSTEONIC Co., Ltd. website. (Screenshot by ReporterKIM JI-WAN )


By product line, Trauma sales rose 52.6% year-over-year, posting the highest growth rate. While domestic sales increased by 10.6%, exports surged by 114.9%. The company explained that orders have been steadily increasing in key regions, such as Central and South America, since receiving approval from the U.S. Food and Drug Administration (FDA) last year.

The Trauma product line is sold under OSTEONIC Co., Ltd.’s own brand without a supply agreement with a global medical device company. This is significant because it indicates that exports of its own-brand products are expanding in addition to the company’s existing business, which relies on the distribution networks of overseas partners.

OSTEONIC Co., Ltd. has global supply agreements in place to provide its Sports Medicine product line to Zimmer Biomet and its CMF product line—cranio-maxillofacial implants—to B. Braun.

The SportsMedicine line includes surgical products that secure damaged soft tissues—such as tendons and ligaments—to bone. A representative product, the suture anchor, is used in suture procedures for conditions such as rotator cuff tears.

Spinal implants also contributed to this growth. Sales of this product line increased by 42.2% compared to the same period last year. The company plans to enhance its competitiveness in the spinal sector by collaborating with Fox Eyes, a U.S.-based developer of spinal surgery navigation robots that it recently acquired.

The acquisition of Fox Eyes is a move to expand the company’s business scope from implant supply to equipment that supports surgical procedures. OSTEONIC Co., Ltd. envisions creating synergies across its product lines by integrating its AI-based spinal surgery navigation robot with its own spinal implants.

Meanwhile, OSTEONIC Co., Ltd. plans to make phased investments in Fox Eyes to expand its surgical robotics business. In addition to the approximately 3 billion won invested to secure a 51% stake, the company plans to invest an additional 7 billion won by 2028, bringing the total investment to 10 billion won. FoxEyes plans to apply for 510(k) clearance from the U.S. Food and Drug Administration (FDA) in the fourth quarter of this year and aims to obtain approval and launch commercial operations next year.

Economy

Corporation

IT·Science

Economy

LGELECTRONICS Enhances Safety and Quality of Humanoid Robots…Aiming to Secure Reliability Early On

LGELECTRONICS is partnering with the Korea Robot Industry Promotion Agency to enhance the safety and quality competitiveness of humanoid robots. Ahead of the unveiling of a bipedal robot in the first …
2026-11-16 10:09:25

Corporation

OSTEONIC Co., Ltd. Reports Cumulative Third-Quarter Revenue of 39.8 Billion… 'Exports Surpass Domestic Sales'

OSTEONIC Co., Ltd.(226400)reported cumulative sales of 39.8 billion won for the first three quarters of this year, driven by expanded overseas sales. Overseas sales slightly exceeded domestic sales in…
2026-11-16 13:11:02

IT·Science

OSTEONIC Co., Ltd.: Exports Surpass Domestic Sales in Q3… European Sales Up 77%

OSTEONIC Co., Ltd.(226400)’s exports surpassed its domestic sales in the third quarter of this year. This is the result of expanded overseas sales, driven primarily by dental implants sold on credit. …
2026-11-16 13:00:03